Evotec bags a CNS pipeline in buyout deal; AMRI bets $41M on contract manufacturing;

@FierceBiotech: Gilead scrambles toward hep C cure-all with next-gen combo pill. News | Follow @FierceBiotech

@JohnCFierce: Novartis chairman vows to preserve top R&D budget in retrenchment. More | Follow @JohnCFierce

@DamianFierce: EU smiles on Lilly and Boehringer's FDA-rejected diabetes drug. Story from Friday | Follow @DamianFierce

@EmilyMFierce: Guinea confirms fever is Ebola, has killed up to 59. Story via Reuters | Follow @EmilyMFierce

> Evotec has bought up Germany's Bionamics to get its hands on some translational therapies for neurodegeneration and central nerve system disorders. Story

> Contract developer AMRI ($AMRI) is trading $41 million for Cedarburg Pharmaceuticals, which manufactures APIs for drugmakers. Item

> Alabama biotech Innovative Med Concepts is developing a novel treatment for fibromyalgia, targeting what the company's founder believes is the viral cause of the disease. Article

Medical Device News

@FierceMedDev: Who is the top med tech company in terms of revenue? Report | Follow @FierceMedDev

@MarkHFierce: Which of the big med tech manufacturers LOST revenue in 2013? Report | Follow @MarkHFierce

@MichaelGFierce: ICYMI: MedImmune inks licensing deal with Bioasis for brain delivery platform. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Alcat test uncovers food sensitivities, and could provide a "balance sheet for the body." Article | Follow @EmilyWFierce

> GE finalizes $1B Thermo Fisher Scientific deal, snatches up 3 business units. More

> South Korea targets medical device industry as its latest growth engine. Item

> St. Jude aims to jump-start the cardiac device space with new pacers and defibrillator leads. Story

Pharma News

@FiercePharma: And the top-read special report: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: Top-read FiercePharma: Tokyo hospital exec says #Novartis employees deeply involved in leukemia-drug trial. Story | Follow @TracyStaton

@EricPFierce: The FDA says it will boost foreign plant inspections 40%, and cut them by same amount in US. More | Follow @EricPFierce

@CarlyHFierce: Novartis' vaccine unit gets a badly needed booster from the U.K. Article | Follow @CarlyHFierce

> Politicians add fuel to the firestorm over Gilead's hep C drug pricing. Story

> Cost watchdogs demand efficacy data on new Bayer cancer drugs. News

> The color purple knocks back Novartis' Advair rival in Germany. More

CRO News

> AMRI bets on manufacturing with $41M Cedarburg buyout. News

> Parexel eyes Asian trials with Singapore expansion. Story

> GVK plots a $16.5M Indian expansion as it dials up its global presence. News

> TKL cuts the ribbon on a new Phase I operation. Article

> Risk-sharing researcher Evotec buys an academic pipeline. News

> CMO Recipharm plots a $142M Swedish IPO. Brief

Biotech IT News

> NY Genome Center taps IBM's Jeopardy!-winning Watson to speed data analysis. News

> Novo Nordisk edges forward with plans to spin off its IT unit. Story

> How will Google's forays into genomics play out? Article

> J&J collaboration with San Diego Supercomputer Center speeds genome analysis. Story

> Cancer gamification project analyzes 1.5M chromosomes in one month. Story

> Merck exec: Health IT apps need more scientific rigor. Brief

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.